ClinicalTrials.gov
public full text
Public Domain
Compensatory Reserve Index (CRI) for Management of COVID-19
The FDA has approved the CipherOx CRI T1 Tablet for use in subjects aged 19-36, and that this study aims to evaluate the device in subjects aged outside of this range and is being used off label. The FDA determined the Cipher OX CRI T1 Tablet to be a class II device in 2016, and additional research has been done since the FDA determination to further support the use of the device outside of its current labeling.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Outcome und Prognoseparameter ECMO-pflichtiger COVID-19-Patienten#1015152
- Natural History Study of COVID-19 Using Digital Wearables#857093
- COVID-19 Among Healthcare Workers in Belgian Hospitals#881343
- Health Care Cybersecurity Challenges and Solutions Under the Climate of COVID-19: Scoping Review#976530
- Expanded Access to Zofin for Patients With COVID-19#869645
Record · ID 1420922
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive